Centegen granted sanofi's Merial subsidiary an exclusive, worldwide license to develop and commercialize Centegen's CEN-102 vaccine against Staphylococcus aureus infections for veterinary applications

Centegen Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

sanofi-aventis Group

France / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced